With Deadline Looming, Novartis Yet To Reach Fee-For-Service Contracts
This article was originally published in The Pink Sheet Daily
Novartis has not entered into fee-for-service contracts with any of its distributors, Novartis Pharmaceuticals CEO Paolo Costa said March 15
You may also be interested in...
Approximately four of McKesson’s “larger manufacturer” partners have not reached, and are not in talks on, fee-for-service contracts. McKesson will not necessarily drop manufacturers that do not reach a formal agreement as long as the economics continue to work, CEO Hammergren says.
The manufacturer maintains that wholesalers "purchase and resell products for their own account and not as a service to Pfizer." Cardinal will no longer distribute Eisai products, including the Alzheimer's drug Aricept, marketed in partnership with Pfizer.
Cardinal's progress in signing fee-for-service distribution contracts with pharmaceutical manufacturers has "accelerated" since the wholesaler set a March 31 contract deadline